Inventiva (NASDAQ:IVA) Shares Up 5.7% - Should You Buy?

Key Points

• Inventiva shares rose 5.7% to $3.4450 in mid-day trading, though volume was about 32% below the stock’s average daily volume.
• Analysts remain broadly optimistic, with an average “Buy” rating and a $15.86 price target; Truist and Guggenheim recently raised their targets to $18 and $14, respectively.
• Inventiva is a clinical-stage biotechnology company developing lanifibranor for MASH, with the drug currently being evaluated in the Phase 3 NATiV3 trial. The company reported a quarterly loss of $0.14 per share and expects a full-year loss of $0.81 per share.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price was up 5.7% on Wednesday. The stock traded as high as $3.39 and last traded at $3.4450. Approximately 666,986 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 977,604 shares. The stock had previously closed at $3.26.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IVA. Truist Financial raised their price objective on Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, October 2nd. Guggenheim upped their target price on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Wall Street Zen raised shares of Inventiva from a "sell" rating to a "hold" rating in a research report on Saturday, October 3rd. Piper Sandler restated an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They set an "overweight" rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Inventiva currently has an average rating of "Buy" and an average price target of $15.86.

Inventiva Price Performance

The company has a 50-day moving average price of $3.98 and a two-hundred day moving average price of $4.43.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. On average, research analysts predict that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Trading of Inventiva

Several large investors have recently modified their holdings of the stock. Platt Investment Counsel LLC bought a new position in shares of Inventiva during the 3rd quarter worth about $45,000. Engineers Gate Manager LP boosted its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after acquiring an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in Inventiva in the first quarter worth approximately $1,111,000. Institutional investors and hedge funds own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.